ANDAs Could Reference Discontinued Labeling Under Proposed FDA Guidance
Executive Summary
FDA is trying to head off efforts by brand name companies to extend product exclusivity through labeling changes.
You may also be interested in...
FDA Should "Raise The Bar" For NDA Supplement Exclusivity, Teva Says
FDA should maintain higher standards for awarding exclusivity for NDA supplements to prevent abuse of the Waxman-Hatch amendments by innovator firms, Teva maintained in comments on FDA's draft guidance on discontinued labeling.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011